Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IDEAYA Biosciences (IDYA) Cash from Investing Activities (2019 - 2025)

Historic Cash from Investing Activities for IDEAYA Biosciences (IDYA) over the last 7 years, with Q3 2025 value amounting to $41.8 million.

  • IDEAYA Biosciences' Cash from Investing Activities rose 30845.98% to $41.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$29.6 million, marking a year-over-year increase of 9290.67%. This contributed to the annual value of -$502.6 million for FY2024, which is 21716.0% down from last year.
  • According to the latest figures from Q3 2025, IDEAYA Biosciences' Cash from Investing Activities is $41.8 million, which was up 30845.98% from $45.9 million recorded in Q2 2025.
  • IDEAYA Biosciences' 5-year Cash from Investing Activities high stood at $79.8 million for Q1 2025, and its period low was -$354.0 million during Q1 2024.
  • In the last 5 years, IDEAYA Biosciences' Cash from Investing Activities had a median value of -$10.3 million in 2022 and averaged -$31.4 million.
  • Per our database at Business Quant, IDEAYA Biosciences' Cash from Investing Activities plummeted by 238813.56% in 2022 and then surged by 37483.27% in 2023.
  • IDEAYA Biosciences' Cash from Investing Activities (Quarter) stood at -$413000.0 in 2021, then plummeted by 2388.14% to -$10.3 million in 2022, then plummeted by 989.36% to -$111.9 million in 2023, then tumbled by 76.08% to -$197.1 million in 2024, then skyrocketed by 121.19% to $41.8 million in 2025.
  • Its last three reported values are $41.8 million in Q3 2025, $45.9 million for Q2 2025, and $79.8 million during Q1 2025.